Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy
It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban. Therefore, we investigated whether intravenous atosiban injection actually causes hyperglycemia and how...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2021-04-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/48/2/10.31083/j.ceog.2021.02.2364 |
| _version_ | 1828791370670669824 |
|---|---|
| author | Hyun Jin Ko Seong Yeon Hong Jin Young Bae |
| author_facet | Hyun Jin Ko Seong Yeon Hong Jin Young Bae |
| author_sort | Hyun Jin Ko |
| collection | DOAJ |
| description | It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban. Therefore, we investigated whether intravenous atosiban injection actually causes hyperglycemia and how these changes affect newborns. From December 2015 to July 2018, a retrospective study was conducted on 96 mothers who were diagnosed with preterm labor and were administered atosiban at our institution. Maternal blood glucose was measured and compared before and during the administration of atosiban. The paired t-test, independent samples t-test, Chi-square test and Fisher’s exact test were performed using SPSS version 21.0. A statistically significant increase in fasting blood glucose levels was observed during the administration of atosiban, compared with random blood glucose levels before administration (110.7 mg/dL vs. 86.3 mg/dL). The mean postprandial blood glucose level during administration was 170.75 mg/dL. Gestational diabetes, twin pregnancy, preeclampsia, and polyhydramnios did not significantly affect the degree of blood glucose increase. Statistically significant hypoglycemia was observed after performing a neonatal blood test immediately after birth from mothers who used atosiban. The neonates from the group with elevated maternal blood glucose levels exceeding 20 mg/dL showed lower blood glucose levels. No serious side effects other than hypoglycemia were observed. Atosiban administration in pregnant women results in significantly elevated maternal blood glucose, which results in hypoglycemia in neonates after birth. Therefore, neonates from mothers who received atosiban require a blood glucose test and close monitoring after birth. |
| first_indexed | 2024-12-12T02:51:00Z |
| format | Article |
| id | doaj.art-50642a785d7f40fda0946a9693d27fba |
| institution | Directory Open Access Journal |
| issn | 0390-6663 |
| language | English |
| last_indexed | 2024-12-12T02:51:00Z |
| publishDate | 2021-04-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj.art-50642a785d7f40fda0946a9693d27fba2022-12-22T00:40:54ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632021-04-0148225726210.31083/j.ceog.2021.02.2364S0390-6663(21)00077-4Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancyHyun Jin Ko0Seong Yeon Hong1Jin Young Bae2Department of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, 42472 Daegu, KoreaDepartment of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, 42472 Daegu, KoreaDepartment of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, 42472 Daegu, KoreaIt is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban. Therefore, we investigated whether intravenous atosiban injection actually causes hyperglycemia and how these changes affect newborns. From December 2015 to July 2018, a retrospective study was conducted on 96 mothers who were diagnosed with preterm labor and were administered atosiban at our institution. Maternal blood glucose was measured and compared before and during the administration of atosiban. The paired t-test, independent samples t-test, Chi-square test and Fisher’s exact test were performed using SPSS version 21.0. A statistically significant increase in fasting blood glucose levels was observed during the administration of atosiban, compared with random blood glucose levels before administration (110.7 mg/dL vs. 86.3 mg/dL). The mean postprandial blood glucose level during administration was 170.75 mg/dL. Gestational diabetes, twin pregnancy, preeclampsia, and polyhydramnios did not significantly affect the degree of blood glucose increase. Statistically significant hypoglycemia was observed after performing a neonatal blood test immediately after birth from mothers who used atosiban. The neonates from the group with elevated maternal blood glucose levels exceeding 20 mg/dL showed lower blood glucose levels. No serious side effects other than hypoglycemia were observed. Atosiban administration in pregnant women results in significantly elevated maternal blood glucose, which results in hypoglycemia in neonates after birth. Therefore, neonates from mothers who received atosiban require a blood glucose test and close monitoring after birth.https://www.imrpress.com/journal/CEOG/48/2/10.31083/j.ceog.2021.02.2364atosibanpreterm labormaternal hyperglycemianeonatal hypoglycemia |
| spellingShingle | Hyun Jin Ko Seong Yeon Hong Jin Young Bae Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy Clinical and Experimental Obstetrics & Gynecology atosiban preterm labor maternal hyperglycemia neonatal hypoglycemia |
| title | Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy |
| title_full | Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy |
| title_fullStr | Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy |
| title_full_unstemmed | Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy |
| title_short | Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy |
| title_sort | pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy |
| topic | atosiban preterm labor maternal hyperglycemia neonatal hypoglycemia |
| url | https://www.imrpress.com/journal/CEOG/48/2/10.31083/j.ceog.2021.02.2364 |
| work_keys_str_mv | AT hyunjinko pregnancyandneonataloutcomesofhyperglycemiacausedbyatosibanadministrationduringpregnancy AT seongyeonhong pregnancyandneonataloutcomesofhyperglycemiacausedbyatosibanadministrationduringpregnancy AT jinyoungbae pregnancyandneonataloutcomesofhyperglycemiacausedbyatosibanadministrationduringpregnancy |